Jurkat & Raji PD-1/PD-L1 Antagonist Assay (Bio-IC™)

Two cell line bioassay - B lymphocytes & NFAT-Lucia reporter T lymphocytes

ABOUT

Antagonist screening assay for PD-1/PD-L1 axis

InvivoGen offers a cellular assay specifically designed for screening antibody-, Fc-fusion protein-, or small-molecule antagonists of the PD-1/PD-L1 immune checkpoint (IC) axis. This assay is comprised of:

  • Jurkat-Lucia™ TCR-hPD-1: Reporter T cells
  • Raji-APC-hPD-L1: Antigen-presenting cells (APCs)


​These paired cell lines allow the mimicking of the immune synapse between T cells and APCs through the interaction of cell surface molecules delivering T-cell activation and concomitant inhibitory checkpoint signals:
- Signal 1 is delivered upon recognition of a specific [HLA::peptide] complex on Raji APC cells by the T-cell receptor (TCR) on Jurkat effector cells,
- Signal 2 is operated by the interaction of CD80/86 and CD28 at the surface of the Raji APC and Jurkat effector cells, respectively,
- PD-1/PD-L1 IC signal is a regulatory signal that inhibits T-cell activation.

More details More details

 

Assay principle:

This assay relies on the co-culture of Jurkat-Lucia™ TCR-hPD-1 and Raji-APC-hPD-L1 cells.
Jurkat-Lucia™ TCR-hPD-1 cells express a specific TCR and the PD-1 inhibitory IC receptor along with the Lucia luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements.
Raji-APC-hPD-L1 cells express a specific [HLA::peptide] complex and the PD-L1 inhibitory IC ligand.
In the presence of a potent PD-1 or PD-L1 antagonist, the IC-mediated inhibition is blocked and the TCR activation leads to Lucia production. Activation of the reporter T cells can be readily measured using QUANTI-Luc™ 4 Lucia/Gaussia detection reagent (see Figures).

T-cell key features:

  • Stable specific [HLA::peptide]-restricted TCR
  • Stable hCD28 overexpression
  • Stable hPD-1 overexpression
  • NFAT-inducible Lucia luciferase reporter activity

APC key features:

  • Stable specific [HLA::peptide] expression
  • Endogenous hCD80/86 expression
  • Stable hPD-L1 overexpression

Read our review Read our review on Immune Checkpoint Blockade

Learn more about Immune Checkpoint Antibodies Learn more about Immune Checkpoint Antibodies.

Disclaimer:  These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.

SPECIFICATIONS

Specifications

Species
Human
Target

PD-1/PD-L1

Target species

Human

Tested applications

Screening of antibody-based inhibitors of the PD-1/PD-L1 axis, Flow cytometry 

Cell type
Lymphoblastic
Growth properties
Suspension
Tissue origin
Human T lymphocytes & Human B cell lymphoma
Reporter gene
Lucia®
Detection method
Bioluminescence
Antibiotic resistance
Blasticidin
Hygromycin
Zeocin®
G418 (mammalian cells)
Growth medium

Complete IMDM (see TDS)

Mycoplasma-free

Verified using Plasmotest™

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    PD-1/PD-L1 Bio-IC™
  • Cat code: 
    rajkt-hpd1
  • Quantity: 
    3-7 x 10^6 cells (x2)
Includes:
  • 1 vial of Jurkat-Lucia™ TCR-hPD-1 cells
  • 1 vial of Raji-APC-hPD-L1 cells
  • 1 ml of Blasticidin (10 mg/ml)
  • 1 ml of Zeocin® (100 mg/ml)
  • 1 ml of Hygromycin (100 mg/ml)
  • 1 ml of G418 (Geneticin) (100 mg/ml)
  • 1 ml of Normocin® (50 mg/ml)
  • 1 tube of QUANTI-Luc™ 4 Reagent (Lucia luciferase detection reagent)
Notes:

Please note: Both cell lines are sold together and cannot be sold separately.

Shipping & Storage

  • Shipping method:  Dry ice
  • Storage:

    • Liquid nitrogen vapor
    Stability: 20 passages

Details

The activation of T lymphocytes initiates their proliferation and yields a variety of effector functions that allow combating microbial infections, as well as developing tumors. The current paradigm is that full activation of T cells requires at least 2 signals upon contact with antigen-presenting cells (APCs) [1, 2].

Signal 1 is delivered through the interaction of the T cell receptor (TCR) and a specific antigenic peptide associated with an MHC (major histocompatibility complex) molecule on APCs. Signal 2 is delivered through the interaction of CD28, the prototypical T cell co-stimulatory molecule, and its ligands, CD80 or CD86, expressed by the APC. However, a number of other molecules, named immune checkpoints (IC), have been reported to regulate the onset and the limitations of T cell activities. PD-1 (programmed cell death 1) receptor and its ligand, PD-L1, are among the best characterized suppressive immune checkpoints [3].

 

Signal 1: TCR and [HLA::peptide]

The 'classical' and most represented TCR is an 80 to 90 kDa heterodimer composed of one α chain and one β chain. The αβTCR is a transmembrane protein expressed by developing and mature T cells. It features an extracellular ligand-binding pocket and a short cytoplasmic tail. Each αβTCR is restricted to a specific complex made of an antigenic peptide and a class I or class II MHC molecule. Human MHC molecules are also known as HLA (human leukocyte antigen). Because of its short cytoplasmic tail, the TCR, once engaged,  lacks the ability to signal and requires non-covalent association with the CD3 to trigger downstream intracellular signaling and T cell activation [1, 2]. Importantly, signal 1 without co-stimulation results in T cell unresponsiveness or 'anergy', a tolerance mechanism that guards against premature activation.

 

Signal 2: CD28 and CD80/86

CD28 is a homodimeric and transmembrane protein expressed by T cells. Nearly all human CD4+ T cells and 50% of human CD8+ T cells express CD28. The CD28 interaction with CD80 (aka B7-1) or CD86 (aka B7-2) on APCs, in conjunction with TCR engagement, triggers a co-stimulation signal (signal 2). It results in T cell proliferation, cytokine production, cell survival, and cellular metabolism [1, 2].

 

IC signal: PD-1 and PD-L1

— PD-1 (programmed cell death 1; also known as CD279) is a type I transmembrane protein expressed at the cell surface of activated and exhausted conventional T cells. PD-1 is an inhibitory immune checkpoint that prevents T-cell overstimulation and host damage. PD-1 interaction with its ligands PD-L1 and PD-L2 induces inhibition of TCR signaling [3].

— PD-L1 (programmed cell death ligand 1; also known as CD274 or B7-H1) is a transmembrane protein expressed at the cell surface of hematopoietic and nonhematopoietic cells and is induced by pro-inflammatory cytokines, such as in the tumor microenvironment  [3].  PD-L1 is one ligand for PD-1, an inhibitory immune checkpoint receptor that is expressed by activated and exhausted T cells. PD-1:PD-L1 interaction induces inhibition of TCR signaling, thereby preventing T-cell overstimulation and host damage [3].

 

References:

1. Budd R.C. & Fortner K.A., 2017. Chapter 12 - T Lymphocytes. Kelley and Firestein's Textbook of Rheumatology (Tenth Edition). pages 189-206.
2. Smith-Garvin J.E. et al., 2009. T Cell Activation. Ann. Rev. Immunol. 27:591-619.
3. Ribas A. and Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.

DOCUMENTS

Documents

PD-1/PD-L1 Bio-IC™

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?